Status:
COMPLETED
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Lead Sponsor:
AstraZeneca
Conditions:
Severe Eosinophilic Asthma
Eligibility:
All Genders
Brief Summary
Benralizumab is a humanised, afucosylated, monoclonal antibody against the interleukin (IL)-5 receptor (IL-5R) α subunit that induces direct, rapid, and near-complete depletion of eosinophils in blood...
Detailed Description
This is a multicentre, single arm, non-interventional observational, prospective study that will include patients older than 18 years, who qualify for the treatment with benralizumab according to the ...
Eligibility Criteria
Inclusion
- Subject eligible for enrolment in the study and treatment for benralizumab according to the specific Russian label and in line with reimbursement condition must meet all the following criteria:
- Male or female patients older than 18 years with physician's confirmed diagnosis of severe, uncontrolled asthma.
- Asthma requiring high-dose ICS plus LABA as maintenance treatment.
- Minimum of 2 exacerbations in the last 12 months. Or 1 exacerbation in case that patient had been receiving oral glucocorticoid therapy for at least 6 continuous months directly before enrollment (equivalent to a prednisolone or prednisone dose of 7.5 to 40.0 mg per day)
- Documented peripheral blood eosinophil count ≥ 300 cells/μL or ≥150 cells/μL blood in case that patient had been receiving oral glucocorticoid therapy for at least 6 continuous months directly before enrollment (equivalent to a prednisolone or prednisone dose of 7.5 to 40.0 mg per day).
- Provision of signed written ICF indicating that they understand the purpose of the study and procedures required for participation in the study.
- Patients must be able and willing to read and comprehend written instructions and comprehend and complete the questionnaires required by the protocol (SGRQ, ACQ-5, PGIC and PGIS).
Exclusion
- Patients who have previously received benralizumab prior to the start of the study.
- Documented lung diseases other than asthma, e.g. COPD, and not within reimbursed label, e.g pregnancy or lactation.
- Concomitant treatment with any other biologic for any indication or previous treatment with biology. Acceptable wash-out periods for other asthma biologics: ≥4 month or duration of 5 half-lives from last dose of previous biologic. We choose what is longer the 5 half-life or 4 months.
- Currently enrolled in an interventional clinical study in parallel, except:
- Patients being in parallel documented in a national asthma registry.
- Patients having completed any other clinical trial including those with biologic treatment ≥4 month or duration of 5 half-lives from last dose of previous biologic. We choose what is longer the 5 half-life or 4 months.
- An acute or chronic condition that, in the investigator's opinion, would limit the patients' ability to complete questionnaires or participate in this study or impact the interpretations of results.
Key Trial Info
Start Date :
May 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 13 2023
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT05271526
Start Date
May 16 2022
End Date
November 13 2023
Last Update
October 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
City clinical hospital No57
Moscow, Russia, 105077